Related references
Note: Only part of the references are listed.CCR 20th Anniversary Commentary: Immune-Related Response Criteria-Capturing Clinical Activity in Immuno-Oncology
Axel Hoos et al.
CLINICAL CANCER RESEARCH (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
New modalities of cancer treatment for NSCLC: focus on immunotherapy
Marianne Davies
CANCER MANAGEMENT AND RESEARCH (2014)
When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression
Geoffrey R. Oxnard et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
Axel Hoos et al.
SEMINARS IN ONCOLOGY (2010)
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables
James R. Anderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma
Richard F. Little et al.
BLOOD (2006)
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma
WHJ Kruit et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the functional assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument
KJ Yost et al.
VALUE IN HEALTH (2005)
The functional assessment of cancer therapy-BRM (FACT-BRM): A new tool for the assessment of quality of life in patients treated with biologic response modifiers
J Bacik et al.
QUALITY OF LIFE RESEARCH (2004)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) study 5592
D Cella et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
